Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02928978 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib for Premalignant Breast Disease
A Phase 2 study of Ductal Carcinoma In Situ and Atypical Ductal Hyperplasia, sponsored by Julie Nangia.
- Active
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 8
- Study locations
NCT02928978 is a Phase 2 study of Ductal Carcinoma In Situ and Atypical Ductal Hyperplasia that is active but no longer recruiting, run by Julie Nangia. The registered enrollment target is 100 participants, below the 251-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (60% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT02928978, a Phase 2 study of Ductal Carcinoma In Situ and Atypical Ductal Hyperplasia, is active but no longer recruiting, sponsored by Julie Nangia.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery to remove the premalignant breast tissue.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG Placebo (for Ruxolitinib)
Study Locations (8)
Texas
- University of Texas MD Anderson Cancer Center - Houston
- Harris Health System - Smith Clinic - Houston
- O'Quinn Medical Tower - McNair Campus; Dan L Duncan Comprehensive Cancer Center - Houston
Alabama
- University of Alabama at Birmingham - Birmingham
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
New York
- Montefiore Medical Center - The Bronx
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-05-13 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02928978
The ClinicalTrials.gov registry entry for NCT02928978 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 251-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (60% lower). The listed sponsor is Julie Nangia, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Ductal Carcinoma In Situ appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT02928978 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Texas, Alabama, Indiana.
Frequently Asked Questions
What is clinical trial NCT02928978 about?
NCT02928978 is a clinical study titled "Ruxolitinib for Premalignant Breast Disease". This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitini...
What is the current status of trial NCT02928978?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2018-05-13. Estimated completion is 2026-06.
What conditions does trial NCT02928978 study?
This clinical trial studies the following conditions: Ductal Carcinoma In Situ, Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, Lobular Carcinoma In Situ.
What interventions are being tested in trial NCT02928978?
The interventions under investigation include: Ruxolitinib (DRUG), Placebo (for Ruxolitinib) (DRUG).
Who is sponsoring clinical trial NCT02928978?
This trial is sponsored by Julie Nangia, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02928978 being conducted?
This trial has 8 study locations across Alabama, Indiana, New York, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ductal Carcinoma In Situ
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
RECRUITING · Phase 2
-
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
RECRUITING · Phase 2
-
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
RECRUITING
-
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
RECRUITING · NA
-
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
RECRUITING · NA
-
Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.